Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CPRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CPRX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Catalyst Pharmaceuticals Inc

CPRX
Current price
20.95 USD -0.76 USD (-3.50%)
Last closed 21.62 USD
ISIN US14888U1016
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 665 153 792 USD
Yield for 12 month +23.31 %
1Y
3Y
5Y
10Y
15Y
CPRX
21.11.2021 - 28.11.2021

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Address: 355 Alhambra Circle, Coral Gables, FL, United States, 33134

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

34.29 USD

P/E Ratio

13.92

Dividend Yield

Financials CPRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CPRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+491 734 000 USD

Last Year

+398 204 000 USD

Current Quarter

+141 421 000 USD

Last Quarter

+141 820 000 USD

Current Year

+422 889 000 USD

Last Year

+313 672 000 USD

Current Quarter

+123 510 000 USD

Last Quarter

+110 833 000 USD
EBITDA 269 168 992 USD
Operating Margin TTM 44.81 %
Price to Earnings 13.92
Return On Assets TTM 18.59 %
PEG Ratio
Return On Equity TTM 29.11 %
Wall Street Target Price 34.29 USD
Revenue TTM 534 646 016 USD
Book Value 6.51 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 43.60 %
Dividend Yield
Gross Profit TTM 446 456 000 USD
Earnings per share 1.57 USD
Diluted Eps TTM 1.57 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 136.80 %
Profit Margin 36.91 %

Stock Valuation CPRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 13.92
Forward PE 11.66
Enterprise Value Revenue 3.85
Price Sales TTM 4.98
Enterprise Value EBITDA 7.65
Price Book MRQ 3.32

Technical Indicators CPRX

For 52 Weeks

15.34 USD 26.58 USD
50 Day MA 23.58 USD
Shares Short Prior Month 7 728 086
200 Day MA 22.40 USD
Short Ratio 6.79
Shares Short 8 168 909
Short Percent 8.10 %